Target Now utilizes advanced molecular profiling analysis to provide a more detailed molecular ‘blueprint’of a patient’s tumor as an aid to the treating oncologist. The comprehensive report provides information on unique molecular targets present and also describes potential associated treatment options from literature.

Through advanced DNA, RNA and protein analysis, Target Now typically identifies multiple unique genes, gene expressions and proteins in each patient’s tumor. These targets are listed in order of expression within the tumor. Additionally, Target Now provides information on associated drugs, including non-standard-of care associations, that may potentially have greater efficacy or be resisted if these targets are present based on research publications and clinical studies.

Target Now can be of value for:

• Patients refractory to second line standard of care therapy;
  
• Patients with rare tumor types having less well-defined or ‘research only’ treatment protocols; or
  
• Select patients diagnosed with very aggressive cancers having an very high mortality rate with first line standard of care therapy (e.g., pancreatic cancer); or
• Select patients that have yet to undergo first line therapy but have significant co-morbidities
  that could preclude standard treatment options.

Given the rapid pace of discoveries of biomarkers and their associations with therapies, Target Now is constantly evolving to incorporate the most current research findings. The clinicians who request Target Now are invited to join the Target Now Physician Network, whereby they can offer insight into their experiences with the test as well as request research into new markers and therapeutic associations. Additionally, in certain circumstances, Target Now may be accessed through our ongoing research study.

Flexible testing platform for all malignancies

Solid and non-solid tumors
      • Formalin fixed paraffin embedded (FFPE) and/or fresh-frozen tissue
              – DNA microarray (gene expression)
              – Protein immunohistochemistry (IHC) analysis
              – FISH
              – Gene sequencing
              – Light microscopic (and molecular) review of the tumor diagnosis

Personalized integrated report

• Quantitative results
• List of potentially druggable or resistant molecular target(s) common to tumors typically independent of lineage
                  – Evidence-based approach for target selection
• List of associated therapeutics from research (for informational purposes only)
                  – Integration of relevant scientific literature and research review

Provider reimbursement

Reimbursed by Medicare and other third party payors
A balance bill to patients is not sent except co-pays and deductibles as required by law.

For more information, contact Caris Dx at 800-591-2610 or www.targetnow.com